摘要
目的 :检测原发性胆囊癌中TGF β1、CyclinE蛋白阳性 ,在其癌发生、发展过程中的表达特点及其在诊治中的临床意义。方法 :应用免疫组化S P法检测 36例原发性胆囊癌中TGF β1、CyclinE的阳性率 ,并以同期 2 0例慢性胆囊炎作对照。结果 :①TGF β1蛋白阳性率为 6 3.89% (2 3/ 36 )显著高于其相应良性对照组 10 % (2 / 2 0 )。Cy clinE蛋白阳性率为 4 7.2 2 % (17/ 36 )显著高于其相应良性对照组 10 % (2 / 2 0 )。②TGF β1蛋白在有淋巴结或远处转移、NevinⅣ~Ⅴ期患者中阳性率 (79.17% )明显增高于无转移、NevinⅠ~Ⅲ期的患者 (33.33% )。CyclinE在低分化、有淋巴结或远处转移阳性率 (84 .6 2 %、6 2 .5 0 % ) ,明显高于高中分化、无转移 (2 6 .0 9%、16 .6 7% )。③CyclinE与TGF β1两者呈正相关 (P <0 .0 5 )。④TGF β1阳性患者生存率明显低于TGF β1阴性患者。CyclinE阳性患者生存率明显低于CyclinE阴性患者。结论 :①在原发性胆囊癌细胞中TGF β1、CyclinE蛋白阳性率表达上调 ,且在有淋巴结或远处转移、NevinⅣ~Ⅴ期患者中更为明显。②联合检测TGF β1、CyclinE蛋白在原发性胆囊癌中阳性有助于反映原发性胆囊癌生物学特性、为预后判断提供参考指标 ,并为探索原发性胆囊癌早期诊断提供实验依据。
Purpose:To investigate the expression of TGF-β1,Cyclin E in (primary) gallbladder carcinoma and its clinical significance. Methods:The expression of TGF-β1,Cyclin E in gallbladder carcinoma was detected by S-P immunohistochemical staining,20 cases of chronic cholecystitis were collected as control. Results:①The positive rate of TGF-β1(63.89%),Cyclin E(47.22%) in gallbladder carcinoma increased significantly(P<0.05).②The positive rate of TGF-β1 was higher in metastasis or Nevin Ⅳ-Ⅴ stage group of gallbladder carcinoma than in non-metastasis or Nevin Ⅰ-Ⅲ stage group(P<0.05).In metastasis or low differentiation there was also higher expression of Cyclin E(P<0.05). ③The expression of Cyclin E was inversely correlated with the expression of TGF-β1(P<0.05). ④There was significant difference in survival time between patients with TGF-β1+ and TGF-β1-. The difference was also shown between patients with Cyclin E + and Cyclin E-. There were statistically signiticant correlations between the first group and the second group. Conclusions:①The up regulation of TGF-β1,Cyclin E in gallbladder carcinoma indicates the imbalance of TGF-β1/ Cyclin E system and might play a role in tumor pathology and prediction of the malignant behavior of the carcinoma.②The detection of TGF-β1,Cyclin E may be useful in assessing the development of the cancer,judging prognosis and eventually render a possible target for novel therapeutic strategies.
出处
《中国癌症杂志》
CAS
CSCD
2004年第4期317-320,共4页
China Oncology